<DOC>
	<DOCNO>NCT00179829</DOCNO>
	<brief_summary>The purpose study determine WT1 adequate measurement minimal residual disease leukemic patient .</brief_summary>
	<brief_title>WT1 Detection Minimal Residual Disease</brief_title>
	<detailed_description>Patients acute Leukemia may large number leukemic cell time leukemia evident clinically . At time determine patient complete remission ( CR ) patient may still leukemic cell present small quantity . One important factor successful treatment patient leukemia ability determine eradication leukemia achieve . The determination Minimal Residual Disease may important determination therapy give patient receive determine level residual disease . WT1 gene function expression . The WT1 gene candidate gene Wilms tumor , think arise result inactivation allele WT1 gene locate chromosome 11p13 . The WT1 gene consider tumor suppressor gene intragenic deletion mutation find tumor , germline mutation find in-patients leukemia , mediate growth suppression Wilms tumor cell express WT1 splice variant .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<criteria>Age le 21 year age . Patients follow disease : Acute lymphoblastic Leukemia ( ALL ) time diagnose relapse , Acute nonlymphoblastic leukemia ( ANLL ) diagnosis relapse Chronic Myelogenous leukemia chronic accelerate phase . Patients eligible available treatment protocol protocols stem cell transplantation , regardless source stem cell . Patients legal guardian sign Institutional Review Board ( IRB ) approve informed consent . Patients venous access peripheral vein sampling .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>leukemia</keyword>
	<keyword>acute lymphocytic leukemia</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>acute myelogenous leukemia</keyword>
</DOC>